Clear Filter

Apr 08, 2015

AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015

NORTH CHICAGO, Ill., April 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation during The International Liver CongressTM (ILC) 2015 in Vienna, Austria from April 22-26. Data being presented include sub-analyses of the recently approved VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets), Phase 3b studies, including a head-to-head comparison of AbbVie's three direct-acting antiviral treatment with telaprevir-based therapy and Phase 2/3 studies investigating AbbVie's combination treatment in genotype 1 (GT1) and genotype 4 (GT4). Additionally, data from Phase 1 studies of ABT-493 and ABT-530 will be presented.

Apr 01, 2015

AbbVie's HUMIRA® (Adalimumab) Approved by European Commission to Treat Children and Adolescents with Severe Chronic Plaque Psoriasis

– HUMIRA is the only Biologic Approved in Europe for Children and Adolescents from Four Years of Age with Severe Chronic Plaque Psoriasis –

Apr 01, 2015

AbbVie CF Scholarship Application for Students with Cystic Fibrosis Now Available for 2015-2016 Academic School Year

NORTH CHICAGO, Ill., April 1, 2015 /PRNewswire/ -- AbbVie today announced that the 2015 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now open to undergraduate and graduate students. Students can apply for the scholarship from now until May 27, 2015, 10 a.m. Central time by visiting

Mar 19, 2015

AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy

NORTH CHICAGO, Ill., March 19, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.  This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's Disease.

Mar 17, 2015

AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting

NORTH CHICAGO, Ill., March 17, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from 22 abstracts on HUMIRA® (adalimumab) and dermatological diseases will be presented at the upcoming 73rd Annual Meeting of the American Academy of Dermatology (AAD), March 20 – 24, in San Francisco. AbbVie's presence at AAD demonstrates the company's commitment to the field of dermatology, which is grounded in HUMIRA. HUMIRA is one of the most comprehensively studied biologics available, and is distinguished by 12 years of physician and patient experience in dermatology.

Mar 06, 2015

AbbVie to Present at Barclays Global Health Care Conference

NORTH CHICAGO, Ill., March 6, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Health Care Conference on Thursday, March 12, 2015. Richard A. Gonzalez, chairman and chief executive officer, will participate in a question and answer session at 8:30 a.m. Central time.

Mar 04, 2015

AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise

NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset  Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies.   The acquisition accelerates AbbVie's clinical and commercial presence in oncology, strengthening its already robust pipeline, and establishing its strong leadership position in hematological oncology – an attractive and rapidly growing market, now approaching $24 billion globally.  The acquisition adds to AbbVie's already comprehensive pipeline and strong growth prospects.

Feb 27, 2015

AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic Plaque Psoriasis

– Marketing Authorization Decision Expected from the European Commission in the Second Quarter –

Feb 26, 2015

AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting

NORTH CHICAGO, Ill., Feb. 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 15 abstracts of studies in its neuroscience and oncology development programs have been accepted for presentation during the 67th American Academy of Neurology annual meeting in Washington, D.C., from April 18-25. The accepted abstracts feature results from studies evaluating AbbVie's FDA-approved product, DUOPA, in addition to investigational treatments in AbbVie's pipeline. Presentations will include Phase 1 results from a study of ABT-414 in patients with glioblastoma multiforme, Phase 3 data for ZINBRYTA™ (daclizumab high-yield process), which is being developed jointly with Biogen Idec, in relapsing remitting multiple sclerosis, and results from a study of DUOPA (carbidopa and levodopa) enteral suspension in advanced Parkinson's disease.